Please login to the form below

Not currently logged in
Email:
Password:

Plasticell names Aaron Chuang as chief scientific officer

He joins from GSK, where he served as a research director

Regenerative medicine firm Plasticell has appointed Dr Aaron Chuang as chief scientific officer.

Chuang joins from GlaxoSmithKline, where he served as research director at the regenerative medicine unit for over 18 years. Chuang initiated the first stem cell drug discovery programme at GSK in 2004 and was central in the firm's stem cell R&D.

Commenting on his appointment, Chuang said: “I am delighted to be joining Plasticell, especially as I have followed closely the company and its innovative technologies for well over 10 years.”

Chuang was an industrial advisor on high profile stem cell initiatives including UK Stem Cell Initiative, UK Cell Therapy Catapult and the California Institute of Regenerative Medicine. 

He was also prominent in establishing GSK's alliance with the Harvard Stem Cell Institute in 2008 and coordinated all collaborative projects.

Dennis Saw, CEO at Plasticell, said: “I am delighted to welcome Aaron to the management team. His scientific background, product development experience and understanding of the industry will be invaluable as we further develop our cell therapy pipeline and expand our network of collaborators.”

19th June 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics